Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2017)
18 slides from Adalta's shareholder meeting presentation, Nov 14, 2017
Slide 1: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease AGM November 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) [email protected]
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta 2017 AGM Agenda
ADALTA 2017 AGM AGENDA For personal use only Chairman introduction AGM formal proceedings CEO presentation 3
Slide 4: Corporate and investment summary
Corporate and investment summary For personal use only A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. Investment highlights Initial focus on tre
Slide 5: Financial position
Financial position For personal use only Key Financial Details ASX code 1AD Share price (10 November 2017) AU$0.20 Market capitalisation AU$20.3m Shares on issue* 101,257,434 Escrowed shares (August 2018) 24,000,000 Options on issue 969,427 Current cash (30 September 17) AU$6.87m Trading range (sinc
Slide 6: AD-114 efficacy and safety
AD-114 efficacy and safety For personal use only Efficacy Safety – Lung: IPF – NHP studies: • Animal models • PK: IV and SC • Human IPF tissue • Dose range finder • Biomarker assessments • Multi dosing studies (Alfred Health & others) – PK-PD assays developed – Broad fibrotic application demonstrati
Slide 7: Achievements over last months
Achievements over last 12 months For personal use only Manufacturing agreement of AD-114 kicked off with Fuji Innovation Connection Grant with Alfred Health; a collaboration with local IPF clinicians to evaluate AD-114 as a biomarker Presented at a number of international conferences including Disco
Slide 8: Some of our FY17 media and analyst coverage
Some of our FY17 media and analyst coverage For personal use only “Patersons readies ASX-hopeful, AdAlta” “AdAlta hopes to take a bite out of fibrosis market with shark-based drug” “Breakthrough for local biotech as influential backer emerges” “I-bodies continue to make progress” “AdAlta on track fo
Slide 9: Initiatives that drove awareness and engagement
Initiatives that drove awareness and engagement For personal use only • Fibrosis Symposium in February 2017 was well attended by investors and analysts, with follow up investor/analyst reports from Partersons, NDF Research and Bioshares • Integrated campaigns for IPF awareness month across AdAlta’s
Slide 10: Financial operating results
Financial operating results For personal use only The Company reported a loss for the year ended 30 June 2017, after accounting for income tax benefit, of ($2,832,517) (30 June 2016: ($1,163,056)). The Company remains in a solid cash position with ~$6.87 million cash in the bank as at 30 September 2
Slide 11: Management and Board in place to deliver strategy
Management and Board in place to For personal use only deliver strategy Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody compa
Slide 12: Scientific Advisory Board
Scientific Advisory Board For personal use only Internationally recognised with proven track record of drug development Dr Mick Foley, AdAlta CSO John Westwick: pulmonary drug Expert in phage display discovery and development NIH, NHMRC, ARC, Gates funding and over 70 Over 14 years experience at Nov
Slide 13: AdAlta business model – strategy to create value
AdAlta business model – strategy to For personal use only create value Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 14: Market benchmarks
Market benchmarks For personal use only Fibrosis Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS lead AD-114 $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen April-16 with Abbvie May -17 with AZ July-17 with Sanofi a
Slide 15: IPF Phase II readouts generate $1.4billion market value
IPF Phase II readouts generate $1.4billion market For personal use only value (NASDAQ:FGEN) $869 million added to its market cap on announcement (7 August 2017) of meeting primary endpoint in Phase IIb study Pamrevlumab (FG-3019) 103 patients 48 weeks (Euronext:GLPG; NASDAQ:GLPG) $555 million added
Slide 16: AD-114 development: key milestones
AD-114 development: key milestones For personal use only FY2018 FY2019 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Manufacturing Partnering of lead candidate Toxicology based on other studies benchmark deals Phase I Publication of data BD and partnerships 16
Slide 17: Expected newsflow next months
Expected newsflow next 12 months For personal use only H1 2017 ü Orphan Drug Designation (US FDA) ü Presentation at partnering meetings including Biotech Showcase 2017, San Francisco ü Data available from AD-114 NASH animal studies ü Manufactured material for toxicology testing available H2 2017 ü S
Slide 18: AdAlta summary
AdAlta summary For personal use only IPO August 2016 raised $10M to meet major milestones: phase I clinical trials of AD-114 in lung fibrosis and development of i-body pipeline Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need AD-114